KR20080056714A - ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법 - Google Patents

ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법 Download PDF

Info

Publication number
KR20080056714A
KR20080056714A KR1020087005714A KR20087005714A KR20080056714A KR 20080056714 A KR20080056714 A KR 20080056714A KR 1020087005714 A KR1020087005714 A KR 1020087005714A KR 20087005714 A KR20087005714 A KR 20087005714A KR 20080056714 A KR20080056714 A KR 20080056714A
Authority
KR
South Korea
Prior art keywords
taci
administered
dose
patient
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087005714A
Other languages
English (en)
Korean (ko)
Inventor
헤르베 브롤리
에릭 시에베르스
아르나우드 이티어
샤론 제이. 버즈비
스테펀 엠. 엔셀
얀 외르스트롬
이반 네스토로브
Original Assignee
지모제넥틱스, 인코포레이티드
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치
아레스 트레이딩 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지모제넥틱스, 인코포레이티드, 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치, 아레스 트레이딩 에스.에이. filed Critical 지모제넥틱스, 인코포레이티드
Publication of KR20080056714A publication Critical patent/KR20080056714A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087005714A 2005-08-09 2006-08-09 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법 Ceased KR20080056714A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70691205P 2005-08-09 2005-08-09
US60/706,912 2005-08-09

Publications (1)

Publication Number Publication Date
KR20080056714A true KR20080056714A (ko) 2008-06-23

Family

ID=37672215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087005714A Ceased KR20080056714A (ko) 2005-08-09 2006-08-09 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법

Country Status (15)

Country Link
US (1) US7842292B2 (https=)
EP (1) EP1922080A2 (https=)
JP (1) JP2009507777A (https=)
KR (1) KR20080056714A (https=)
CN (1) CN101262876A (https=)
AR (1) AR059945A1 (https=)
AU (1) AU2006278229B2 (https=)
CA (1) CA2618765A1 (https=)
EA (1) EA016083B1 (https=)
IL (1) IL188403A (https=)
MX (1) MX2008001661A (https=)
NO (1) NO20081149L (https=)
UA (1) UA93516C2 (https=)
WO (1) WO2007019575A2 (https=)
ZA (1) ZA200801354B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
JP2009537563A (ja) * 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
SG182191A1 (en) * 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8728730B2 (en) * 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
US20170247462A1 (en) 2014-07-03 2017-08-31 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
CA2075182C (en) 1990-02-09 2003-03-25 David J. Mangelsdorf Retinoid receptor compositions and methods
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
DE69535634T2 (de) 1994-12-15 2008-08-28 Yeda Research And Development Co., Ltd. Modulatoren der funktion des fas/ap01 rezeptors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
JP2000500014A (ja) 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
CA2261020C (en) 1996-07-17 2004-06-08 Zymogenetics, Inc. Preparation of pichia methanolica auxotrophic mutants
ES2248823T5 (es) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
JP2002517977A (ja) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303424A1 (en) 1997-09-12 1999-03-18 Jurg Tschopp Kay - a novel immune system protein
SK3542000A3 (en) 1997-09-12 2000-08-14 Apotech R & D Sa Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
DE19831987A1 (de) 1998-07-16 2000-01-20 Bayer Ag Diphenylimidazoline
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
EP1141278B1 (en) 1998-12-30 2008-02-27 Oligos Etc. Inc. Therapeutic pde4d phosphodiesterase inhibitors
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
BR0007719A (pt) 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
DE60040147D1 (de) 1999-05-28 2008-10-16 Targeted Genetics Corp Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen
UA75049C2 (uk) 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2006201471B2 (en) 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
JP2004513876A (ja) * 2000-04-27 2004-05-13 バイオジェン　インコーポレーテッド 抗−腫瘍剤としてのｔａｃｉ
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
KR100886276B1 (ko) 2000-08-11 2009-03-04 기린 파마 가부시끼가이샤 인산 대사, 칼슘 대사, 석회화 및 비타민 ｄ 대사를조절하는 폴리펩티드 및 그것을 코딩하는 ｄｎａ
ES2329012T3 (es) 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules

Also Published As

Publication number Publication date
ZA200801354B (en) 2009-08-26
EA200800560A1 (ru) 2008-06-30
UA93516C2 (ru) 2011-02-25
MX2008001661A (es) 2008-04-07
AU2006278229B2 (en) 2011-10-27
AU2006278229A1 (en) 2007-02-15
EP1922080A2 (en) 2008-05-21
US20070071760A1 (en) 2007-03-29
IL188403A (en) 2011-06-30
AR059945A1 (es) 2008-05-14
IL188403A0 (en) 2008-08-07
EA016083B1 (ru) 2012-02-28
NO20081149L (no) 2008-04-30
WO2007019575A2 (en) 2007-02-15
CA2618765A1 (en) 2007-02-15
CN101262876A (zh) 2008-09-10
US7842292B2 (en) 2010-11-30
JP2009507777A (ja) 2009-02-26
WO2007019575A3 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
RU2750821C2 (ru) Препараты антител против her2 для подкожного введения
CN101489573B (zh) 用TACI-Ig融合分子治疗自身免疫疾病的方法
JP7752152B2 (ja) 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ
IL188403A (en) Pharmaceutical compositions for treating b-cell malignancies using taci-ig fusion molecule and methods for use thereof
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
EP2621516B1 (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
IL188404A (en) Use of taci-fusion molecules in the preparation of a pharmaceutical composition for the treatment of multiple myeloma
CN105770891A (zh) TACI-Ig 融合蛋白如ATACICEPT 用于制备治疗红斑狼疮的药物的用途
KR20210094584A (ko) Gdf15 유사체 및 체중을 감소시키고/시키거나 음식 섭취량을 감소시키는 데 사용하기 위한 방법
KR20190024572A (ko) TNFα 관련 질환을 치료하기 위한 피하 투여 요법
HK1121039A (en) Methods for treating b-cell malignancies using taci-ig fusion molecule
HK1128426A (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080307

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110805

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130410

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20140219

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140915

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140219

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20130410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I